Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2676-2678

  Baranwal, Somesh ^a   Dey, Keya ^a   Ramamurthy, T ^a   Nair, G Balakrish ^a   Kundu, Manikuntala ^a  

^a BOSE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; NORFLOXACIN; OFLOXACIN; PROTEIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; PRIMER DNA; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DRUG EXCRETION; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTON MOTIVE FORCE; VIBRIO CHOLERAE; BACTERIAL GENE; BACTERIAL GENOME; CHOLERA; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; CHOLERA; DNA GYRASE; DNA PRIMERS; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MICROBIAL; GENES, BACTERIAL; GENOME, BACTERIAL; HUMAN; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPORT, NON-U.S. GOV'T; VIBRIO CHOLERAE; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS;

EID: 0035992024     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2676-2678.2002     Document Type: Article

References (17)

1. Neisseria gonorrhoeae acquires mutations in analogous regions of GyrA and ParC in fluoroquinolone-resistant isolates
2. Double-blind, randomized, controlled clinical trial of norfloxacin for cholera
3. Isolation and characterization of a putative multidrug resistance pump from Vibrio cholerae
4. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae
5. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae O139 infection
6. Expanding multiple antibiotic resistance among clinical strains of Vibrio cholerae isolated from 1992-7 in Calcutta, India
7. Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae
8. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli
9. Clinical applications of quinolones
10. New topoisomerase essential for chromosome segregation in E. coli
11. Transduction of linked genetic characters of the host by bacteriophage P1
12. DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities
13. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump
14. Cholera in Piura, Peru: A modern urban epidemic
15. Cholera in the Americas
16. Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents